Orthofix Medical Inc. (OFIX) fair value analysis

Nasdaq · Updated 2026-09-07

Orthofix Medical Inc. is a medical device company that develops and manufactures orthopedic and spine products, including biologics, orthobiologics, and fixation devices for surgical and non-surgical applications. The company operates globally, serving patients and healthcare providers across multiple international markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, OFIX is trading at more than a 25% discount to estimated fair value.

OFIX currently ranks #23 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $12.26
Sector: Healthcare
12-month range: $9.27–$16.06

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: Low
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The lower-middle quarter of its range

What our data shows for OFIX

Our model validated 13 trailing price-to-earnings windows for OFIX, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $9.27–$16.06.
The 14-day relative strength index sits at a neutral 32.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for OFIX
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent OFIX news

TickrTrends' derived news-sentiment signal for OFIX is currently mixed, computed from recent coverage.

Orthofix Medical Inc (OFIX) Insider Sell: President, Global Limb Recon Patrick Fisher Disposes of 150 Shares (gurufocus.com, 2026-09-04)
TickrTrends take: An insider sale of this magnitude represents a relatively modest transaction, though valuation-focused investors typically monitor insider dispositions as signals of management confidence. Given TickrTrends' current undervalued assessment of OFIX within the Healthcare sector, this particular sell activity warrants observation to determine whether it reflects broader concerns about the company's prospects or represents routine portfolio management by an executive. Readers tracking the stock should continue monitoring insider transaction patterns and any accompanying regulatory filings for additional context about management's view of the company's current valuation levels.
Orthofix Medical Inc. Q2 2026 Earnings Call Summary (finance.yahoo.com, 2026-08-05)
TickrTrends take: I don't have access to the specific details from Orthofix Medical Inc.'s Q2 2026 earnings call summary, so I cannot provide factual statements about what was discussed or announced. To write accurately for a stock research page, I would need the actual earnings call content or a detailed summary of the financial results and guidance provided. If you can share the specific facts from that earnings call, I would be happy to relate them to TickrTrends' undervalued designation for OFIX within the Healthcare sector.
Orthofix Medical Inc. Q2 2026 Earnings Preview (NASDAQ:OFIX) (seekingalpha.com, 2026-08-04)
TickrTrends take: Orthofix Medical Inc. is preparing to report second quarter 2026 earnings, which will provide an opportunity to assess whether the company's operational performance supports TickrTrends' current undervalued assessment. Investors focused on valuation metrics should monitor revenue trends, profitability margins, and any updates to guidance that could justify or challenge the current pricing in the Healthcare sector. The earnings report will be a key data point for determining whether OFIX's market valuation properly reflects the company's underlying business fundamentals.

What people are saying

Follow the OFIX conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for OFIX showed movement this week as the Relative Strength Index transitioned from oversold territory into neutral range, suggesting reduced downward momentum in the Healthcare sector stock. The current valuation verdict remains Undervalued according to TickrTrends' assessment.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is OFIX stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), OFIX is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is OFIX's TickrTrends verdict?

OFIX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does OFIX compare to other Healthcare stocks?

OFIX ranks #23 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is OFIX overbought or oversold?

OFIX's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

OFIX vs DXCM · OFIX vs HQY · OFIX vs HSTM · OFIX vs IDXX · OFIX vs ISRG